Find Academic Supervisors

Katrin J SvenssonView profile

Associate Professor

• Metabolic Disorders
• Peptide Hormones
• Proteomics
• +5 more

Dr. Katrin J Svensson is an Associate Professor of Pathology at Stanford University and Affinity Group Leader at the Stanford Diabetes Research Center. She received her Ph.D. from Lund University (2012) and completed postdoctoral training at Harvard Medical School/Dana-Farber Cancer Institute (2017). Her research focuses on discovering circulating factors and peptide hormones that regulate metabolism through computational, proteomic, and physiological approaches. Key discoveries: Isthmin-1 (glucose/lipid homeostasis), BRINP2-related peptide (anti-obesity effects), ANGPTL3 (fructose metabolism) Academic Affiliations: Bio-X, Cardiovascular Institute, Wu Tsai Human Performance Alliance, MCHRI Faculty Fellow Research Highlights: Mapping tissue-specific peptide secretion to identify orphan ligands Characterizing receptors like GPR151 for glucose regulation Developing mitochondria-targeted therapies for cancer and metabolic diseases Investigating dietary sugar impacts on systemic metabolism Scientific Awards: Churg Research Award (2019) McCormick and Gabilan Award (2018) NIH K99/R00 Pathway to Independence Award (2016-2021) SRC International Postdoctoral Fellowship (2013-2016) Teaching & Mentorship: Leads Advanced Cell Biology courses (BIO 214/BIOC 224/MCP 221) and mentors graduate students/postdoctoral researchers in Biochemistry, Biophysics, and Cancer Biology programs.

Xiaohui XuView profile

Professor

• Environmental Epidemiology
• Air Pollution
• Maternal and Child Health
• +5 more

Xiaohui Xu is a Professor in the Department of Epidemiology & Biostatistics at Texas A&M University, specializing in environmental epidemiology. Her research focuses on the health impacts of air pollution, maternal and child health, genetic susceptibility, and spatial epidemiology. She collaborates extensively with institutions in China and the United States on population health studies. Education: PhD in Epidemiology, University of Pittsburgh (2007) MA in Environmental Health, Fudan University (2002) MD in Preventive Medicine, Zhejiang University (1999) Xu’s work explores how environmental exposures interact with genetic and pre-existing health conditions to affect outcomes in vulnerable populations. Her studies span respiratory health, cardiovascular effects of pollution, heavy metal toxicity in HIV patients, and adverse birth outcomes linked to air quality. She employs advanced exposure assessment techniques and spatial modeling. Recent publications highlight her focus on prenatal particulate matter exposure, gestational diabetes, ozone health effects, and pollution mitigation strategies. Collaborative trials include air purifier efficacy studies and community-based interventions for asthma management. Her research bridges environmental science, public health, and clinical epidemiology. Xu holds appointments in environmental health policy and contributes to understanding pollution’s role in chronic disease progression. Her work informs regulatory frameworks and health interventions in high-risk populations, including agricultural communities and urban asthma sufferers.

• Thyroid Physiology
• Thyroid Pathology
• Thyroid Cancer
• +4 more

Dr. Carole Ann Spencer is a Professor at the University of Southern California, specializing in Research Medicine. She holds a PhD from Glasgow University, Scotland, and has completed fellowships in Clinical Biochemistry at Glasgow University and at the National Academy of Clinical Biochemistry. Her work focuses on advancing thyroid-related diagnostics and clinical practices, particularly in immunoassay techniques and thyroid hormone metabolism. Her research interests include thyroid physiology/pathology, thyroglobulin and thyroid cancer biomarkers, optimizing thyroid hormone suppression therapy for differentiated thyroid cancer (DTC), and studying thyroid dysfunction during pregnancy. She emphasizes the development of cost-effective diagnostic methodologies and addressing challenges in clinical endocrinology. Awards: Endocrine Society International Award for Publishing Excellence (2011) 2× Distinguished Scientist Awards from National Academy of Clinical Biochemistry (2004) and Clinical Ligand Assay Society (1998) Multiple Outstanding Speaker recognitions from the American Association for Clinical Chemistry (1998, 1997, 1992) Albert L. Chaney Award (2003) and Gold Medal from London Academy of Music and Dramatic Art (1967) Her advising and grant activities are not detailed in the provided text. She contributes to collaborative efforts in endocrinology and clinical biochemistry, though specific labs or research teams are not mentioned here.

Henk-Jan GuchelaarView profile

Professor

• Clinical Pharmacy
• Pharmacogenetics
• Personalised Therapeutics
• +3 more

Henk-Jan Guchelaar is a Professor of Clinical Pharmacy at Leiden University Medical Center (LUMC) and the Leiden Academic Center for Drug Research (LACDR), part of Leiden University's Faculty of Science. He holds dual appointments across the Faculty of Medicine and Faculty of Science, reflecting his interdisciplinary focus in clinical pharmacy and translational research. As Chair of the Department of Clinical Pharmacy & Toxicology at LUMC, he leads research in personalized therapeutics and pharmacogenomics. He directs Leiden University’s Translational Drug Discovery and Development research profile and coordinates the EU-funded Horizon 2020 project Ubiquitous Pharmacogenomics (UPGx), advancing pre-emptive pharmacogenomic testing. His education includes a Pharmacy degree from Rijksuniversiteit Groningen, followed by specialization as a hospital pharmacist and clinical pharmacologist. He has authored over 540 peer-reviewed articles (H-index=51) and co-developed the Master of Pharmacy program at LUMC. His leadership roles include membership in the Dutch Medicines Evaluation Board, the Royal Dutch Academy of Sciences’ Council for Medical Sciences, and former vice-chairmanship of the Dutch Society for Clinical Pharmacology and Biopharmacy (NVKFB). Research interests focus on optimizing drug therapy through pharmacogenetic insights, particularly in oncology and personalized medicine. Notable projects include genotype-guided dosing of fluoropyrimidines and tamoxifen metabolism studies in breast cancer. Awards include the 2018 PGRN Featured Investigator and NVKFB Education Award. Professional activities include advisory roles for the Dutch Medicines Evaluation Board and EU consortia. He has led national and international initiatives, such as the CYPTAM study on tamoxifen pharmacogenetics, and founded the Leiden Network for Personalised Therapeutics (LNPT). His work bridges clinical practice, academia, and policy to improve drug safety and efficacy through precision approaches.

• Oncology
• Clinical Trials
• Gastrointestinal Cancers
• +3 more

Associate Professor Katrin Sjoquist is a Senior Research Fellow and Clinical Lead at the NHMRC Clinical Trials Centre (CTC), part of the Faculty of Medicine and Health at the University of Sydney. She is also a practising medical oncologist specializing in gastrointestinal and rare cancers. Since joining the CTC in 2010, she has focused on clinical trials in oncology, earning a PhD in clinical trial design and evaluation. Her roles include coordinating the AGITG trials and leading the Cancer Australia-funded Genomics Cancer Clinical Trials Initiative (GCCTI) and the Molecular Screening and Therapeutics (MoST) programme. Research Interests: Design and management of Phase II/III clinical trials, evidence-based medicine, gastrointestinal and rare cancers, and evaluating treatment benefits versus harms. Her work spans oncology drug development, precision medicine, and translational research. Publications: Over 100 peer-reviewed articles, including high-impact studies in Journal of Clinical Oncology , Clinical Cancer Research , and British Journal of Cancer . Recent work focuses on regorafenib in gastric cancer, cell-free DNA biomarkers, and clinical trial methodologies. Grants and Leadership: Principal investigator on grants such as the Biliary Tract Registry Development (2023), and leadership roles in international trials like INTEGRATE II and NuTide:121. Collaborates with institutions like the Garvan Institute. Labs/Teams: CTC, AGITG, and MoST programme. Her work emphasizes collaborative, multi-institutional research to advance oncology treatments.

Lei DuanView profile

Associate Professor

• Cancer Therapy Resistance
• Molecular Mechanisms of Cancer
• Autophagy Regulation
• +3 more

Lei Duan is an Associate Professor in the Department of Anatomy & Cell Biology at Rush University Medical Center. His primary affiliation is with Rush Medical College. Dr. Duan's research focuses on understanding molecular mechanisms of cancer therapy resistance, particularly in breast and lung cancers. He holds an MD from Shanghai Jiaotong University Medical School, China. His laboratory investigates prolyl peptidases' role in endocrine therapy resistance in ER+ breast cancer and targets such as MCL1 and Aurora kinases in small cell lung cancer. His work integrates basic and translational research, collaborating with Carl Maki, PhD. Key areas include autophagy regulation, PI3K/AKT/mTOR signaling, and epigenetic modifications (e.g., histone demethylases). He has over 70 peer-reviewed publications and maintains active collaborations with institutions like NIH and Scopus. His lab is part of the Cell & Molecular Medicine Research Division at Rush. Notable projects involve developing biomarkers for therapy sensitivity and studying RTK signaling pathways. Dr. Duan's work bridges mechanistic discoveries with potential clinical applications in oncology.

Michael D. JensenView profile

Professor

• Obesity Research
• Adipose Tissue Metabolism
• Diabetes
• +3 more

Michael D. Jensen, M.D., is a Professor of Medicine at Mayo Clinic with a primary appointment in the Division of Endocrinology, Diabetes, Metabolism, and Nutrition. His research focuses on obesity's impact on health, particularly adipose tissue function and its role in metabolic disorders. He serves as Editor-in-Chief of Obesity and holds an honorary professorship at Aarhus University. Dr. Jensen leads studies on fatty acid metabolism, insulin resistance, and body fat distribution, employing advanced techniques including isotope dilution, biopsy analysis, and molecular biology. Education: BA in Biology (University of Missouri, Kansas City), MD (University of Missouri School of Medicine), and residency/fellowship training at Mayo Clinic. Key roles: Consultant in Endocrinology, Principal Investigator on NIH-funded projects. His research investigates how adipose tissue dysfunction contributes to diabetes and cardiovascular disease, with a focus on regional fat distribution and metabolic pathways. Dr. Jensen has pioneered methods to measure fatty acid turnover and has developed the Adipose Tissue Analysis Toolkit (ATAT) for studying adipocyte biology. Major awards include the George Bray Outstanding Scientific Achievements Award (2023) and the Thomas J. Watson Professorship (2013). His work bridges clinical practice and translational research, aiming to improve therapies for metabolic disorders.

Dimitrios KarampinosView profile

Professor

• Magnetic Resonance Imaging (MRI)
• Biomedical Engineering
• Medical Imaging Technology
• +6 more

Prof. Dimitrios Karampinos is a Professor at the Technical University of Munich (TUM), leading the Experimental Magnetic Resonance Imaging group within the TUM School of Medicine and Health. He specializes in developing novel MRI techniques for quantitative biomarker discovery, focusing on musculoskeletal, metabolic, and oncological applications. His career includes a PhD from the University of Illinois (2008), postdoctoral research at UCSF (2009–2012), and leadership roles at TUM since 2012. Prof. Karampinos has pioneered advancements in MRI reconstruction, signal modulation, and biomarker validation for clinical translation. Educations: BSc in Mechanical Engineering (National Technical University of Athens, Greece), PhD in Biomedical Engineering (University of Illinois, Urbana-Champaign, 2008). Research Interests: Development of MRI measurement techniques, quantitative biomarkers for disease diagnosis, and improving therapy monitoring. Key areas include musculoskeletal disease imaging, metabolic disorder assessment, and oncology applications. His work emphasizes translating research into clinical practice through innovations like accelerated imaging, artifact correction, and AI-driven analysis. Awards: ERC Starting and Proof of Concept Grants (2015, 2019), TUM Supervisory Award (2020), ISMRM Junior Fellow (2011). Grants: Multiple ERC grants for MRI method development. Labs/Teams: Leads the Experimental Magnetic Resonance Imaging group at TUM, collaborating on clinical and technical MRI advancements.

• Obesity
• Diabetes
• Bariatric Surgery
• +5 more

Roman Vangoitsenhoven serves as an Assistant Professor at KU Leuven's Faculty of Medicine within the Department of Chronic Diseases and Metabolism. He leads the Subdivision Metabolic unit at the Clinical and Experimental Endocrinology research group (UZ Herestraat 49, box 7003, 3000 Leuven) and holds membership in both the Council of the Faculty of Medicine and the Council of the Department of Chronic Diseases and Metabolism. His research focuses on obesity and diabetes, with particular emphasis on GLP-1 based pharmacotherapy , bariatric surgery outcomes , and cardiometabolic health optimization . Current projects investigate neuropsychobiological approaches to patient selection for weight management therapies, de novo serine biosynthesis in obesity-related cardiac dysfunction, and data-driven interventions for type 2 diabetes management in diverse populations including low-income settings and urban Uganda. Analysis of his 2025 publications reveals a strong thematic concentration on translational obesity research , with recurring subfields spanning pharmacotherapy mechanisms, surgical outcomes, nutritional interventions, and metabolic monitoring technologies. His work demonstrates consistent collaboration across European institutions with significant contributions to clinical guidelines development. Member of Faculty of Medicine Council Member of Department of Chronic Diseases and Metabolism Council Dr. Vangoitsenhoven actively supervises multiple major research projects including a €2.3M ERC-funded study on GLP-1 pharmacotherapy optimization (2025-2029) and international collaborations on diabetes management in low-resource settings. His teaching portfolio includes advanced courses in clinical nutrition, disease mechanisms, and evidence-based medicine within KU Leuven's medical curriculum. He leads the Clinical and Experimental Endocrinology unit's metabolic research subdivision, directing a multidisciplinary team of 12 researchers focused on obesity-diabetes pathophysiology and therapeutic interventions. Current initiatives include the SABO cohort study on post-bariatric sarcopenia in elderly patients and development of digital health tools for personalized diabetes management.

• Surgical Oncology
• Breast Cancer
• Geriatric Oncology
• +12 more

Professor Lynda Wyld is a leading academic and clinician in surgical oncology at the University of Sheffield, affiliated with the School of Medicine and Population Health. She serves as Professor of Surgical Oncology and is an Honorary Consultant Breast Surgeon at the Jasmine Breast Centre, Doncaster. Her extensive clinical and research work focuses on improving outcomes for older women with breast cancer. Lynda Wyld earned her medical degree (MBChB) and PhD from the University of Sheffield in 1990. She completed basic surgical training in Leeds and higher surgical training across Sheffield, Nottingham, and Manchester. She was appointed Consultant and Senior Lecturer at the University of Sheffield in 2002. Her research interests center on surgical oncology, particularly breast cancer in older women, treatment decision-making, quality of life, and de-escalation of therapy. She leads the multicentre 'Age Gap' trial, which investigates optimal care pathways and decision support tools for older women with breast cancer. Her work also spans psychosocial outcomes in familial breast cancer, epigenetic modifiers of BRCA, and axillary surgery trends. Her recent publications (2023–2025) reflect a strong focus on geriatric oncology, patient-reported outcomes, and surgical decision-making. Key themes include frailty assessment, long-term outcomes of breast reconstruction, patient satisfaction with mastectomy without reconstruction, and global trends in axillary surgery de-escalation. Her research combines clinical trials, cohort studies, and qualitative methods. Chief Investigator, Age Gap Trial Collaborator with University of Cardiff, SCHARR, and Sheffield Hallam University Active contributor to European guidelines in breast cancer surgery Professor Wyld has supervised and collaborated with numerous researchers and clinicians, including J. Morgan, M. Reed, K. Collins, and others. She has no listed scientific awards in the provided text. She leads a multidisciplinary research group focused on improving cancer care for older and vulnerable populations.

Vivian L. ChinView profile

Assistant Professor

• Pediatric Endocrinology
• Diabetes
• Obesity
• +2 more

Vivian L. Chin is an Assistant Professor of Pediatrics at SUNY Downstate Health Sciences University, specializing in Pediatric Endocrinology. She practices at SUNY Downstate and Kings County Hospital Center, focusing on diabetes, obesity, PCOS, and disorders of sexual development. Education: BA in Biology, Cornell University New York University School of Medicine Residency at Children's Hospital at Montefiore Fellowship at NYP Columbia University/Morgan Stanley Childrens Hospital Her research interests include metabolic disorders and hormonal conditions in adolescents, with publications on topics like diabetes, obesity, and genetic mutations in endocrine diseases. Dr. Chin actively participates in pediatric residency training and serves as Vice Chair of SUNY Downstate's IRB, ensuring ethical standards in research.

John J. WerohaView profile

Associate Professor

• Ovarian Cancer Therapeutics
• PARP Inhibitors
• Personalized Medicine
• +3 more

Dr. John J. Weroha is an Associate Professor of Oncology at Mayo Clinic, with affiliations in the Department of Oncology and Mayo Clinic Comprehensive Cancer Center. He specializes in gynecologic malignancies and phase 1 clinical trials, focusing on personalized cancer therapy using patient-derived xenografts (PDX) and molecular targeted therapies. Dr. Weroha holds academic ranks in Oncology, Pharmacology, and Medicine. Academic Roles: Associate Professor of Oncology, Mayo Clinic College of Medicine Clinical Focus: Gynecologic oncology, phase 1 trials, and precision medicine Institutional Affiliations: Mayo Clinic Comprehensive Cancer Center, Mayo Medical School Education MD: University of Kansas School of Medicine (2007) PhD: University of Kansas School of Medicine (2007), Pharmacology, Toxicology & Therapeutics BS: University of Kansas (1998), Cellular Biology Fellowship: Hematology/Oncology, Mayo School of Graduate Medical Education (2013) Research Interests Dr. Weroha's research bridges laboratory innovations with clinical applications, emphasizing: Development of novel therapeutic combinations for ovarian cancer Mechanisms of resistance to PARP inhibitors Use of PDX models to predict treatment responses Strategies for overcoming therapeutic resistance Integration of next-generation sequencing for personalized therapy Scientific Contributions His work has advanced understanding of: PARP inhibitor mechanisms in ovarian cancer Senolytics' role in aging and disease Molecular pathways driving metastasis Awards & Honors Top 20% Mayo Clinic Department of Medicine Teaching Faculty (2014) Chief Clinical Investigator, Mayo Graduate School (2010) Multiple honors for academic excellence (1998–2005) Clinical & Professional Roles Dr. Weroha leads: Mayo Clinic Ovarian Cancer SPORE (2015–present) Translational Science Program, Mayo Clinic Comprehensive Cancer Center (2023–present) Professional memberships: AACR, ASCO, Society of Gynecologic Oncologists

• Progranulin research
• Neuroprotection
• Tissue repair
• +4 more

Andrew Bateman, PhD is a Senior Scientist at the Research Institute of the McGill University Health Centre (RI-MUHC) at the Glen site, where he leads research in the Metabolic Disorders and Complications Program within the Centre for Translational Biology. He holds a professorship in the Department of Medicine, Faculty of Medicine and Health Sciences at McGill University, with specific affiliation to the Division of Endocrinology at the McGill University Health Centre. Dr. Bateman's research primarily focuses on progranulin, a protein that plays crucial roles in cell communication, neuroprotection, tissue repair, and cancer progression. His work has demonstrated that progranulin instructs nearby cells to divide and move, inhibits cell death caused by challenges such as starvation or chemotherapeutic drugs, and is essential for keeping nerve cells alive. Notably, his research has shown that losing half of the brain's progranulin levels through mutation causes frontotemporal dementia, a devastating degenerative brain disease. His laboratory also investigates how progranulin is overexpressed in many cancers, rendering cancer cells more aggressive, and how blocking progranulin may serve as a route to cancer therapy. Additionally, his work explores progranulin's role in reducing inflammation and promoting wound repair, including angiogenesis, which has potential applications for people suffering from chronic wounds. Analysis of Dr. Bateman's publication record reveals a consistent focus on progranulin across multiple disciplines including neuroscience, molecular biology, oncology, and vascular biology. His research spans from fundamental protein structure and evolution to clinical applications in neurodegenerative diseases and cancer. A notable trend in his work is the exploration of progranulin's dual role in both neuroprotection and cancer progression, highlighting the complex nature of this regulatory protein. His research has evolved from early work on corticostatic peptides and the immune-hypothalamic-pituitary-adrenal axis to his current specialized focus on progranulin's multifaceted biological functions. Dr. Bateman has made significant contributions to understanding the role of progranulin in various physiological and pathological processes. His work has implications for developing therapeutic approaches for neurodegenerative diseases, cancer treatment, and wound healing. He has established himself as a leading researcher in the field of progranulin biology, with numerous publications in high-impact journals spanning several decades of research.

Shu Q. LiuView profile

Professor

• Biomedical Engineering
• Cardiovascular Engineering
• Cell Protective Engineering
• +3 more

Shu Q. Liu is a Professor of Biomedical Engineering at Northwestern University’s McCormick School of Engineering. His research focuses on cell protective engineering, particularly in cardiovascular and neuroprotective contexts, addressing ischemic disorders like heart attacks and strokes. He holds affiliations with the PhD Program in Interdisciplinary Biological Sciences. Education: Ph.D. in Bioengineering (University of California San Diego), M.S. and B.M. in Physiology (Medical School of Neimengu, China). Research Interests: Developing engineering strategies to understand and mitigate cell damage in ischemic conditions. Key areas include vascular smooth muscle cell behavior, biomaterials for arterial reconstruction, and liver-mediated organ protection mechanisms. Scientific Awards: Includes the 1994 Melville Medal (ASME), 1998 Established Investigator Award (American Heart Association), and multiple best paper awards. Advising & Grants: While specific grants are not listed, his work emphasizes translational research bridging engineering and medicine. Students advised are listed in his CV. Labs/Teams: Collaborations focus on biomaterials, cardiovascular engineering, and systems biology approaches to organ protection.

Sarah M. LerchenfeldtView profile

Associate Professor

• Medical Education
• Team-Based Learning
• Peer Feedback
• +3 more

Sarah M. Lerchenfeldt serves as Associate Professor and Interim Co-Chair in the Department of Foundational Medical Studies at Oakland University William Beaumont School of Medicine. Since joining OUWB in 2014 as an assistant professor, she has developed expertise in pharmacology instruction and team-based learning methodologies across the medical curriculum. Her educational background includes: Pharm.D. from Raabe College of Pharmacy, Ohio Northern University ASHP Accredited PGY1 Pharmacy Practice Residency at Harper University Hospital ASHP Accredited PGY2 Oncology Pharmacy Residency at Karmanos Cancer Center Dr. Lerchenfeldt's research centers on teamwork dynamics in health education, with particular focus on peer feedback mechanisms and self-directed team learning. As a certified Team-Based Learning Collaborative Trainer-Consultant, she investigates how collaborative structures impact student outcomes in medical education. Her work bridges pharmacological content delivery with innovative pedagogical approaches, especially in hematology/oncology instruction where she serves as course co-director. Analysis of her publication history reveals consistent scholarly output since 2013, with recent work (2022-2025) emphasizing cognitive load adaptations during disruptive events, systematic reviews of self-directed learning assessment, and pharmacology education innovations. Her research demonstrates increasing specialization in educational methodology rather than clinical pharmacology. Administratively, Dr. Lerchenfeldt provides leadership as Interim Co-Chair while maintaining active classroom roles including pharmacology instruction and hematology/oncology course direction. Her dual expertise in clinical pharmacy and medical education uniquely positions her to develop curriculum that integrates pharmacological principles with team-based clinical reasoning.